FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979556074> ?p ?o ?g. }

• W2979556074 abstract "Abstract Abstract 2030 HSCT after reduced or minimal intensity conditioning is increasingly used to treat AML patients not eligible for conventional HSCT. Short term outcome has been reported frequently and risk factors have been identified; long term results still await in depth evaluation. We report here 5 years follow up results from a prospective phase II study conducted by two AML study groups in Europe. Patients were recruited from AML protocols HOVON/SAKK AML 43 and the OSHO AML 1997 study. The regimen consisted of fludarabine (FLU), 30 mg/m2/d on days −4, −3, and −2, 2 Gy TBI on day 0 (the day of HSCT) with mycophenolate mofetil, [15 mg/kg p.o. b.i.d. from 5 hours after HSCT to day +40], and cyclosporine, [CSP; 6.25 mg/kg p.o. bid from day –3 to day +180] after HSCT. Cyclosporine was adjusted to trough levels and reduced according to a predetermined tapering schedule and donor type. A total of 96 patients were recruited between 5/2002 and 8/2005 in the study. Age was median 62 (range 40 – 74) years, 54 patients were male (56%) and 73 patients (76%) had de novo AML. The remission status on entry was CR1 in 83 (86%) patients and CR2 in 13 (14%). Of the 96 patients, 20% had high risk cytogenetics and SCT was performed a median of 75 days after chemotherapy. There were no statistical differences in the above described characteristics except for more secondary AML (p=0.04) and more CR2 patients (p=0.07) among the 59 unrelated SCT (61%) as compared to the 37 related SCT (39%). Graft rejection at two years was observed in 6% of the patients. Absence of chronic GvHD was diagnosed in 40% and limited chronic GvHD in 29% of the patients, with no difference between related and unrelated SCT. Probability of overall survival (OS) at 6 years with a median follow up of 64 (49–92) months reaches a plateau after 5 years at 0.33±0.05 and was not significantly better in CR1 than in CR2. However, there was a trend towards better OS at 6 years for unrelated 0.41±0.11 as compared to related 0.29±0.07 SCT (p=0.08) in CR1 only. This difference was significant for disease free survival (DFS) (0.48±0.09 unrelated vs 0.27±0.06 related; p=0.04), the major reason being a higher relapse rate in related as compared to unrelated SCT (0.62±0.08 vs 0.40±0.09). The overall non-relapse mortality at 6 years was 0.21±0.05. We conclude that OS and DFS reach a stable plateau from 5 years after SCT to more than 8 years after SCT. In CR1 patients, DFS is superior after unrelated as compared to related SCT. Accordingly, strategies designed to decrease relapse, especially after related SCT, have already been implemented in the ongoing protocols. The preferential use of unrelated rather than related donors may be beneficial and should be considered in future protocols. Disclosures: Off Label Use: Transplantation in elderly patients." @default.
• W2979556074 created "2019-10-18" @default.
• W2979556074 creator A5003455280 @default.
• W2979556074 creator A5005594026 @default.
• W2979556074 creator A5018364683 @default.
• W2979556074 creator A5018592613 @default.
• W2979556074 creator A5034779401 @default.
• W2979556074 creator A5040594919 @default.
• W2979556074 creator A5042734609 @default.
• W2979556074 creator A5046775582 @default.
• W2979556074 creator A5052598232 @default.
• W2979556074 creator A5053069175 @default.
• W2979556074 creator A5055821837 @default.
• W2979556074 creator A5056804809 @default.
• W2979556074 creator A5062839406 @default.
• W2979556074 creator A5066560929 @default.
• W2979556074 creator A5066941082 @default.
• W2979556074 creator A5072582820 @default.
• W2979556074 creator A5078376583 @default.
• W2979556074 creator A5087069801 @default.
• W2979556074 date "2011-11-18" @default.
• W2979556074 modified "2023-10-05" @default.
• W2979556074 title "Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML" @default.
• W2979556074 doi "https://doi.org/10.1182/blood.v118.21.2030.2030" @default.
• W2979556074 hasPublicationYear "2011" @default.
• W2979556074 type Work @default.
• W2979556074 sameAs 2979556074 @default.
• W2979556074 citedByCount "0" @default.
• W2979556074 crossrefType "journal-article" @default.
• W2979556074 hasAuthorship W2979556074A5003455280 @default.
• W2979556074 hasAuthorship W2979556074A5005594026 @default.
• W2979556074 hasAuthorship W2979556074A5018364683 @default.
• W2979556074 hasAuthorship W2979556074A5018592613 @default.
• W2979556074 hasAuthorship W2979556074A5034779401 @default.
• W2979556074 hasAuthorship W2979556074A5040594919 @default.
• W2979556074 hasAuthorship W2979556074A5042734609 @default.
• W2979556074 hasAuthorship W2979556074A5046775582 @default.
• W2979556074 hasAuthorship W2979556074A5052598232 @default.
• W2979556074 hasAuthorship W2979556074A5053069175 @default.
• W2979556074 hasAuthorship W2979556074A5055821837 @default.
• W2979556074 hasAuthorship W2979556074A5056804809 @default.
• W2979556074 hasAuthorship W2979556074A5062839406 @default.
• W2979556074 hasAuthorship W2979556074A5066560929 @default.
• W2979556074 hasAuthorship W2979556074A5066941082 @default.
• W2979556074 hasAuthorship W2979556074A5072582820 @default.
• W2979556074 hasAuthorship W2979556074A5078376583 @default.
• W2979556074 hasAuthorship W2979556074A5087069801 @default.
• W2979556074 hasConcept C126322002 @default.
• W2979556074 hasConcept C141071460 @default.
• W2979556074 hasConcept C2776694085 @default.
• W2979556074 hasConcept C2776755627 @default.
• W2979556074 hasConcept C2777408962 @default.
• W2979556074 hasConcept C2779263901 @default.
• W2979556074 hasConcept C2781413609 @default.
• W2979556074 hasConcept C2911091166 @default.
• W2979556074 hasConcept C71924100 @default.
• W2979556074 hasConcept C90924648 @default.
• W2979556074 hasConceptScore W2979556074C126322002 @default.
• W2979556074 hasConceptScore W2979556074C141071460 @default.
• W2979556074 hasConceptScore W2979556074C2776694085 @default.
• W2979556074 hasConceptScore W2979556074C2776755627 @default.
• W2979556074 hasConceptScore W2979556074C2777408962 @default.
• W2979556074 hasConceptScore W2979556074C2779263901 @default.
• W2979556074 hasConceptScore W2979556074C2781413609 @default.
• W2979556074 hasConceptScore W2979556074C2911091166 @default.
• W2979556074 hasConceptScore W2979556074C71924100 @default.
• W2979556074 hasConceptScore W2979556074C90924648 @default.
• W2979556074 hasLocation W29795560741 @default.
• W2979556074 hasOpenAccess W2979556074 @default.
• W2979556074 hasPrimaryLocation W29795560741 @default.
• W2979556074 hasRelatedWork W2003938723 @default.
• W2979556074 hasRelatedWork W2047967234 @default.
• W2979556074 hasRelatedWork W2118496982 @default.
• W2979556074 hasRelatedWork W2405138071 @default.
• W2979556074 hasRelatedWork W2439875401 @default.
• W2979556074 hasRelatedWork W2594821722 @default.
• W2979556074 hasRelatedWork W2609272607 @default.
• W2979556074 hasRelatedWork W3115595276 @default.
• W2979556074 hasRelatedWork W4238867864 @default.
• W2979556074 hasRelatedWork W2525756941 @default.
• W2979556074 isParatext "false" @default.
• W2979556074 isRetracted "false" @default.
• W2979556074 magId "2979556074" @default.
• W2979556074 workType "article" @default.